CHAOUKI STEVEN M 4

What Happened

• Steven M. Chaouki, a director of MAIA Biotechnology, was granted 26,982 stock options on June 30, 2026. The Form 4 reports the award as a derivative grant at $0.00 consideration (i.e., an option grant rather than a cash purchase or sale).
• The grant was made under MAIA’s 2021 Equity Incentive Plan and the filing shows no immediate sale of shares—this is compensation in the form of options, not an open-market purchase or sale.

Key Details

• Transaction date: 2026-06-30; Form 4 filed: 2026-07-02.
• Instrument: Stock options (derivative) — 26,982 options reported as acquired at $0.00.
• Vesting/exercise: Per the filing footnote, the options vest 100% on the grant date and are exercisable beginning that date (F1).
• Shares owned after transaction: Not reported in this Form 4.
• Timeliness: Filing date is July 2, 2026; no late filing flag indicated in the report.

Context

• These are option awards (compensation), which give the holder the right to buy common stock in the future; they do not represent an immediate purchase of shares or a sale. Such grants are common for executives and directors and are not, by themselves, a clear signal of insider buying or selling intentions.